Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis
Aliment Pharmacol Ther
.
2023 Jan;57(1):150-151.
doi: 10.1111/apt.17237.
Epub 2022 Dec 5.
Authors
Stephen Hanauer
1
,
Yinghong Wang
2
,
Malek Shatila
2
Affiliations
1
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
2
Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
PMID:
36468245
DOI:
10.1111/apt.17237
No abstract available
Publication types
Editorial
Comment
MeSH terms
Adrenal Cortex Hormones* / adverse effects
Colitis* / chemically induced
Colitis* / drug therapy
Humans
Infliximab / adverse effects
Substances
Infliximab
Adrenal Cortex Hormones